Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

17 results about "Monensin" patented technology

Monensin is a polyether antibiotic isolated from Streptomyces cinnamonensis. It is widely used in ruminant animal feeds. The structure of monensin was first described by Agtarap et al. in 1967, and was the first polyether antibiotic to have its structure elucidated in this way. The first total synthesis of monensin was reported in 1979 by Kishi et al.

Preparation method of monensin fermentation liquor

The invention discloses a preparation method of monensin fermentation liquor, relates to the technical field of microbial fermentation, and aims to solve the problems of low titer and long period of the existing process. According to the method, streptomyces cinnamomi is taken as a strain, a culture medium with a specific formula is adopted, and fermentation is performed in three stages: in the first stage (0-30-50 hours), pH is not controlled; in the second stage, a phosphoric acid and compound oil mixed solution (accounting for 1-3% of the fermentation solution, and the compound oil contains 20-30% of peanut oil, 20-30% of corn oil and the like) is supplemented at a time; in the third stage, the pH is controlled to be 6.2-6.3, and soybean oil and sterile water are supplemented according to needs. The fermentation adopts a secondary process, the temperature is controlled at 30-33 DEG C, the dissolved oxygen is more than or equal to 35% and the like, the total duration is less than or equal to 320 hours, and the titer is more than or equal to 55000 mu g / ml. By optimizing the culture medium and precisely regulating and controlling, the element production capacity is improved, the method is suitable for industrial production of tanks of 50 L to 100 m < 3 >, the efficiency is improved, and the cost is reduced.
Owner:SHANGHAI MOXI BIOLOGICAL TECH CO LTD

Fermentation culture medium for improving fermentation titer of monensin as well as preparation method and application of fermentation culture medium

The invention provides a fermentation culture medium for improving the fermentation titer of monensin as well as a preparation method and application of the fermentation culture medium, and belongs to the technical field of microbial fermentation engineering and veterinary drug manufacturing. The mass concentration of the soybean cake powder protease hydrolysate in the fermentation culture medium is 30-40g / L based on the soybean cake powder; the fermentation culture medium further comprises the following components by mass concentration: 30-40 g / L of a carbon source, 10-15 g / L of vegetable oil, 5.15-10.60 g / L of inorganic salt and the balance of water; the pH value of the fermentation culture medium is 6.5-7.5. The soybean cake powder protease hydrolysate is added into the fermentation culture medium, by optimizing the formula of the culture medium, the fermentation period can be remarkably shortened, the fermentation efficiency can be improved, titer increase can be promoted, the yield of monensin can be improved, the production cost of monensin can be reduced, and the fermentation culture medium can be applied to production of antibiotic-monensin.
Owner:INNER MONGOLIA CHINA ANIMAL HUSBANDRY BIO-PHARM CO

Application of monensin in preparation of medicine for inhibiting formation of CAF

The invention provides an application of monensin in preparation of a medicine for inhibiting formation of tumor-associated fibroblasts. Specifically, it is found that monensin can influence the formation process of a tumor microenvironment of targeted tumor-related fibroblast cells, development of solid tumors is effectively inhibited from the source, and then increase of the tumor volume is inhibited.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Recombinant cinnamon streptomyces and application thereof in monensin production

The invention provides recombinant cinnamon streptomyces and application thereof in monensin production, and belongs to the technical field of microbial fermentation and antibiotic preparation. According to the recombinant cinnamon streptomyces provided by the invention, a ccr gene with a nucleotide sequence shown as SEQ ID NO.2 in the cinnamon streptomyces is knocked out, and an xylA gene with a nucleotide sequence shown as SEQ ID NO.1 is overexpressed. According to the recombinant cinnamon streptomyces provided by the invention, through overexpression of the xylA gene, the metabolic capability of the cinnamon streptomyces to xylose is enhanced; the ccr gene is knocked out, so that the carbon catabolism inhibition phenomenon is weakened, and the xylose utilization rate is increased when the recombinant strain takes xylose as a carbon source. The recombinant streptomyces cinnamomi provided by the invention can improve the titer of monensin, reduce the production cost, shorten the fermentation period and improve the production efficiency.
Owner:JIANGNAN UNIV +1

A monensin premix and a method for preparing the same

The application relates to the technical field of feed additives, and discloses a monensin premix and a preparation method thereof.The raw material composition of the monensin premix comprises monensin, a carrier, a surfactant, a binder, amino acid chelated trace elements, vitamin E, ascorbic acid palmitate and coenzyme Q10.The preparation method comprises the following steps: S1, stirring and mixing monensin and the carrier to prepare a mixture I; S2, dissolving the binder in a water bath at 80-100 DEG C, cooling to room temperature, adding the mixture I and the remaining raw materials, and stirring and mixing to prepare a mixture II; S3, uniformly treating the mixture II to prepare an intermediate product; and S4, preparing the intermediate product into granules by using a spray drying method, so that the monensin premix is obtained.The monensin premix prepared by the application is uniform in granularity, good in stability and uniformity, and high in drug efficacy.
Owner:ZHUMADIAN HUAZHONG CHIA TAI CO LTD

Streptomyces cinnamoneus, microbial inoculum, method for synthesizing monensin and application thereof

The present application belongs to the field of microbial technology, and particularly relates to a Streptomyces cinnamoneus, a microbial agent, a method for synthesizing monensin and application. The present application provides a Streptomyces cinnamoneus SDSL6002 with a preservation number of CGMCC No. 30409. The ability of the Streptomyces cinnamoneus SDSL6002 provided by the present application to simultaneously metabolize glucose and xylose is significantly improved, and the Streptomyces cinnamoneus SDSL6002 can simultaneously utilize xylose and glucose to synthesize monensin. The present application further provides a method for synthesizing monensin or improving the yield of monensin. It has been verified that the Streptomyces cinnamoneus SDSL6002 can utilize bagasse enzymolysis liquid to synthesize monensin, and the yield of the synthesized monensin is high.
Owner:JIANGNAN UNIV +1

A medium composition and fermentation process for monensin

PendingCN122445556AMonensinFatty acid
The application belongs to the technical field of microbial fermentation, and particularly relates to a culture medium composition and a fermentation process of monensin. A technical idea of 'inducing endogenous lipase secretion in bacterial cells, in-situ hydrolyzing oil, and dynamically releasing precursor fatty acids' is first proposed, and based on this, a complete fermentation process is developed. By applying a lipase activity inducer, the secretion level of extracellular lipase of Streptomyces cinnamoneus is significantly increased. Compared with the control without adding the inducer, the lipase activity can be increased by 2-4 times, and the titer of monensin is increased by 15%-25%.
Owner:HEBEI SHENGXUE DACHENG PHARMA

Anti-coccidiosis preparation containing nicarbazin and preparation method of anti-coccidiosis preparation

The invention relates to the technical field of anticoccidial drugs, in particular to an anticoccidial preparation containing nicarbazin and a preparation method of the anticoccidial preparation. The anticoccidial preparation containing nicarbazin comprises the following raw materials in parts by mass: 3-7 parts of nicarbazin, 6-14 parts of monensin, 5-10 parts of mesoporous silica, 1-3 parts of chitosan, 1-2 parts of soybean lecithin, 0.1-0.5 part of carboxyl-terminated polyamidoamine, 1-2 parts of an emulsifier, 1-2 parts of a film-forming agent, 1-3 parts of a dispersant and 20-30 parts of vegetable oil. According to the present invention, the bioavailability is effectively improved, the problem of overhigh or overlow local drug concentration is overcome, the poultry can be prevented from being easily poisoned after ingestion, the treatment effect can be improved, the coccidiosis prevention and treatment effect is significant, the poultry growth is effectively promoted, the production cost is effectively reduced, and the batch production and the large-area promotion are easily achieved.
Owner:ZHEJIANG ESIGMA BIOTECH CO LTD

Genetically engineered bacterium for producing monensin and application of genetically engineered bacterium

PendingCN121950647ABacteriaTransferasesCitrate synthaseIsomerase
The invention discloses a genetically engineered bacterium for producing monensin and application of the genetically engineered bacterium, and belongs to the technical field of metabolic engineering. The invention provides a recombinant cinnamon streptomyces capable of increasing the yield of monensin, the recombinant cinnamon streptomyces simultaneously overexpresses phosphofructokinase (pfk), citrate synthase (cs), methylmalonyl coenzyme A isomerase (mutB) and isobutyryl coenzyme A mutase (icm), and the result shows that the recombinant cinnamon streptomyces overexpresses acetyl coenzyme A synthesis and energy supply of the monensin. According to the method, synthesis precursors (methylmalonyl CoA and ethylmalonyl CoA) are increased, the yield of monensin can be increased without increasing the supply of the precursors, the yield can reach 20.4 g / L, the production cost is effectively reduced, and the production benefit is improved.
Owner:JIANGNAN UNIV +1

Application of monensin in preparation of anti-coronavirus drugs

ActiveCN121337790BAntiviralsHeterocyclic compound active ingredientsPharmaceutical drugFeline infectious peritonitis virus
The application discloses application of monensin in preparation of anti-coronavirus drugs, relates to the technical field of new monensin purposes, and the coronavirus has a ribosome frameshift translation regulation mechanism, monensin is used for inhibiting ribosome frameshift, and then inhibiting the coronavirus proliferation. For feline infectious peritonitis virus, the effective concentration of monensin is 0.1 muM-10 muM. For canine coronavirus, the effective concentration of monensin is 0.5 muM-10 muM. The application has the following advantages: small drug resistance risk; low effective concentration; and convenient administration.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Method for improving yield of monensin by constructing anti-oxidation system

The invention provides a method for improving the yield of monensin by constructing an anti-oxidation system, and belongs to the technical field of genetic engineering. The invention provides a method for transforming monensin fermentation strain streptomyces cinnamomi by constructing an endogenous anti-oxidation system, which comprises the following steps: connecting a coding gene of catalase and / or a coding gene of superoxide dismutase with a basic vector such as pSET152 by a homologous recombination method to construct an overexpression recombinant vector; and carrying out overexpression on the gene in streptomyces cinnamomi by using a genetic transformation method. According to the three overexpression strains obtained by the invention, the oxidation resistance of the streptomyces cinnamomi can be improved, ROS (reactive oxygen species) generated in cells can be effectively eliminated, the damage of oxidative stress to thalli can be reduced, particularly, the oxidation resistance of the recombinant strain which jointly overexpresses katX and sod is the highest, and the titer of monensin is improved to the maximum extent.
Owner:XIAMEN UNIV +1

Application of monensin in preparation of anti-coronavirus drugs

ActiveCN121337790AAntiviralsHeterocyclic compound active ingredientsPharmaceutical drugFeline infectious peritonitis virus
The invention discloses application of monensin in preparation of an anti-coronavirus drug, and relates to the technical field of new application of monensin, coronavirus has a translation regulation mechanism of ribosome frame shift, and monensin is used for inhibiting ribosome frame shift so as to inhibit proliferation of the coronavirus. For the cat infectious peritonitis virus, the effective concentration of the monensin is 0.1 mu M to 10 mu M. For canine coronavirus, the effective concentration of the monensin is 0.5-10 [mu] M. The invention has the following advantages: the drug resistance risk is small; the effective concentration is low; the administration is convenient.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

High-efficiency preparation of monensin rabbit monoclonal antibody based on two-step cell selection strategy of single B cell technology

The invention discloses a two-step cell selection strategy for efficiently preparing a rabbit-derived monoclonal antibody based on a single B cell technology. The invention belongs to the technical field of biology, and particularly relates to efficient preparation of a rabbit-derived monoclonal antibody based on a two-step cell selection strategy of a single B cell technology. The antibody is a monoclonal antibody or an antigen binding fragment thereof, and comprises a heavy chain variable region and a light chain variable region, amino acid sequences of HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of the antibody are as shown in 25th to 32th sites, 50th to 56th sites and 93rd to 102nd sites of SEQ ID No: 1; amino acid sequences of LCDR1, LCDR2 and LCDR3 in a light chain variable region of the antibody are shown as the 28th to 33rd sites, the 51st to 53rd sites and the 90th to 100th sites of SEQ ID No: 2.
Owner:CHINA AGRI UNIV

Gene for improving reducing power and producing monensin at high yield through multi-gene synergistic expression, vector and strain

The invention provides a gene for improving reducing power and producing monensin with high yield through multi-gene synergistic expression, a vector and a strain, and belongs to the technical field of gene engineering. The invention provides a donor fusion gene with high reducing power, and the fusion gene can be jointly overexpressed in host bacteria and generate a synergistic effect, so that the total amount of NADPH and NADH in host cells is increased by two times, and sufficient reducing power is provided for biosynthesis of monensin. The invention further provides an expression vector for expressing the fusion gene, the expression vector is transferred into streptomyces such as cinnamon streptomyces, the monensin yield of a recombinant strain can be remarkably increased, the genetic stability is good, and the yield retention rate still reaches 90% or above after five times of continuous passage. According to the method, the combined strong promoter is constructed through simple gene combination and a carrier, so that the reducing power can be efficiently supplied in multiple ways, and the method is suitable for industrial amplification.
Owner:SHANDONG SHENGLI BIOENGINEERING CO LTD

Recombinant vector, recombinant streptomyces cinnamomi and application of recombinant vector and recombinant streptomyces cinnamomi

The invention provides a recombinant vector, recombinant streptomyces cinnamomi and application of the recombinant vector and the recombinant streptomyces cinnamomi, and belongs to the technical field of monensin preparation. The recombinant vector provided by the invention comprises a gene capable of increasing the content of methylmalonyl coenzyme A, a PermE promoter with a nucleotide sequence as shown in SEQ ID NO.3 and an fd terminator with a nucleotide sequence as shown in SEQ ID NO.4, the gene capable of increasing the content of methylmalonyl coenzyme A comprises a branched chain amino acid transaminase gene with a nucleotide sequence as shown in SEQ ID NO. 1 and / or a propionyl coenzyme A carboxylase gene with a nucleotide sequence as shown in SEQ ID NO. 2. According to the method disclosed by the invention, the generation of propionyl coenzyme A in a leucine metabolic pathway and the conversion of propionyl coenzyme A to methylmalonyl coenzyme A are synergistically enhanced, and an efficient precursor supply system is constructed, so that the fermentation yield of monensin is remarkably improved.
Owner:SHANDONG SHENGLI BIOENGINEERING CO LTD

Application of biopesticide in prevention and treatment of tea lesser leafhopper

The invention belongs to the technical field of microbial fermentation and insect pest prevention and control, and particularly relates to application of a biopesticide to prevention and control of tea lesser leafhopper. The bacillus velezensis NM153 supernate is used for treating the tea lesser leafhopper, and the result shows that the tea lesser leafhopper can be observed to die in quantity after being treated for about 12 hours under the treatment of the bacillus velezensis NM153 supernate, and the death rate reaches 52.2%, so that the supernate has good quick-acting property, is suitable for practical application scenes in which insect pests need to be quickly controlled, and has wide application prospects. And the death rate of the tea lesser leafhopper at 24 hours reaches 91.1%. In addition, it is further verified that monensin, natamycin and dehydrohirsutine in metabolites of the bacillus velezensis NM153 have remarkable technical effects on prevention and treatment of tea lesser leafhopper.
Owner:HUNAN INST OF MICROBIOLOGY +1

Method for measuring greenhouse gas emissions of ruminants after administration of feed additive

The present disclosure provides methods for administering monensin and / or 3-nitroxypropanol to an animal in order to provide a reduction in greenhouse gas emissions from the animal. In addition, the described methods effectively provide embodiments for generating and receiving carbon credits due to the reduction in greenhouse gas emissions.
Owner:ELANCO US INC